The rise of cancer immunotherapy such as immune checkpoint modulators, bispecific antibodies, T-cell therapy and personalized cancer vaccines, prompted a wide range of unique challenges. The demand for predictive and robust preclinical approaches to minimize translational failures in immuno-oncology (I/O) is peaking vastly. The need for leveraging phenotypic features of models, for early identification of predictive biomarkers, for rational design of combination therapies, and for researching the cancer-immune cell interactions add to the complexity of translational research in immuno-oncology.
Pharmaseed is working with leading I/O industry leaders to bring such new products to the market. We use the latest techniques and research tools to investigate new CAR-T products and Immune Checkpoint Inhibitors in-vitro and in animals.
We offers a range of preclinical cancer models (subcutaneous tumor xenografts, orthotopic tumor models, isogenic cell lines, etc.). Tumor modeling in-vivo for the study of cancer growth and metastasis are characterized by inoculation of cancer cells in immunosuppressed murines.
The two most used models for the assessment of potential efficacy of tested technology are the xenograft and the orthotopic models. In combination with in-vitro systems, such as angiogenesis and ex-vivo models, such as the HET-CAM, allow the prediction of response can be fully evaluated.
Pharmaseed offers a variety of anti-cancer drug-discovery and development services including screening of compound efficacy in a battery of in vitro assays and in vivo models.
These models include (among others):
- Leukemia and Lymphoma cancer models